[caption id="attachment_70276" align="aligncenter" width="500"] Photo by Polina Tankilevitch[/caption] The FDA has now officially approved Journavx (generic name suzetrigine). This is a breakthrough non-narcotic pain medication that was developed to control pain, whether chronic pain, acute pain, or even cancer pain, without the addictive properties of traditional opioid medication. Touted as a safe option for patients with moderate to severe acute pain, this new pain drug is gaining attention for offering a non-opioid treatment option with minimal side effects and clinically proven results. In this article, we will break down what Journavx is, what makes it different from non-opioid pain meditation, and what its FDA approval means for the future of pain management. We will also explore its application for nerve blocks, how it compares with other medications, and the key clinical data that led to this decision.